Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
about
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study dataThe role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy.Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteersInterpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patientsDevelopment and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patientsPharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.Pharmacologic perspectives for once-daily antiretroviral therapy.Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hoursClinical pharmacokinetics of antiretroviral drugs in older persons.Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.Dosing rationale for fixed-dose combinations in children: shooting from the hip?Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
P2860
Q30652267-A1DC0A1C-EF6C-48E7-8F9D-A200BD7F9DE9Q35073349-0149CB95-BE78-4AA2-9683-A83A4A672594Q35636050-87724C2D-DBFF-4867-974D-15F552DE6706Q35758975-6C339B3F-01FF-4463-A111-184FB1FF1453Q35826686-EE336212-9A47-498F-8829-6453ECD88928Q35846675-308DF0B2-843A-4104-9583-8E2CFAD6B6BDQ35915916-B416395C-548D-41AC-BEF9-180F7BF5A5B5Q36628549-483D2530-A785-405C-8947-4180DEE4143BQ36747438-942F6872-39CD-4B61-BD23-5208F833E15DQ36845126-815D8010-A364-4C24-A2D2-7952D204F84EQ36880866-7D2DC1D6-53EE-4F20-9B26-B70328395764Q36905884-0D346B80-D848-4316-BF72-9946831B9F7FQ40603398-65D85B0D-0AC3-4882-BECD-F682E012AE95Q41720226-F8A123FF-2561-4A4B-A6B4-51A20F9971D3Q44473215-C28A3245-C4E0-415B-870F-ED15377CA452Q44564339-EDD5AC3B-4D48-4D3C-A998-1E18EEA47FD9Q44677507-A35C2B8E-9F8C-4E08-A5FF-1FFB2CC0C74FQ45919623-A0B1B948-A3A7-41ED-A95B-9F18BD77CE5DQ46571246-2077D252-336F-43D6-80A2-513BE4702172Q46770803-9799BDA5-F3BA-4F9B-807F-8518E4A8AA3D
P2860
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@ast
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@en
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@nl
type
label
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@ast
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@en
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@nl
prefLabel
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@ast
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@en
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@nl
P2093
P2860
P1476
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
@en
P2093
Brian M Sadler
Daniel S Stein
P2860
P304
P356
10.1128/AAC.46.3.746-754.2002
P407
P577
2002-03-01T00:00:00Z